The European Medicines Agency (EMA) has published an overview of key recommendations from 2025 on the authorization and safety monitoring of veterinary medicinal products.[1] In 2025, the EMA issued 23 recommendations for new veterinary medicines, including 12 vaccines.[2] EMA has issued the first certificate for a technological vaccine platform that will accelerate the development and authorization of new veterinary vaccines in the EU.[2] From 15 May 2025, a new EMA directive on the benefit-risk assessment of veterinary medicinal products applies, which introduces a structured multi-step approach.[1] Manufacturers must submit more comprehensive data, including clinical trials, environmental risk assessments, and antimicrobial resistance studies throughout the product lifecycle.[1] Based on the opinion of the Committee for Veterinary Medicinal Products, the EMA concluded on 15 January 2025 on five biological substances other than chemical type.[4] New platforms have been launched to collect data on the sale and use of antimicrobials in animals to combat resistance.[2] Some existing veterinary drugs may be withdrawn or restricted if they prove more risky than beneficial.[1]